Evidence map›Paper›PMID 38956199›Full record

ArticleNature medicine2024

Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.

Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua, Donald L Lamm, Edward M Uchio, Daniel M Geynisman, Joseph M Jacob, Joshua J Meeks and 8 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Roger LiDepartment of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Roger.Li@moffitt.org.ORCID http://orcid.org/0000-0003-1274-7200
Paras H ShahDepartment of Urology, Mayo Clinic, Rochester, MN, USA.
Tyler F StewartDepartment of Medicine, UC San Diego, La Jolla, CA, USA.
Jong Kil NamPusan National University, Yangsan Hospital, Yangsan, South Korea.
Trinity J BivalacquaDepartment of Urology, University of Pennsylvania, Philadelphia, PA, USA.
Donald L LammBCG Oncology, Phoenix, AZ, USA.
Edward M UchioDepartment of Urology, UC Irvine, Irvine, CA, USA.
Daniel M GeynismanDepartment of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Joseph M JacobDepartment of Urology, SUNY Medical Center, Upstate, Syracuse, NY, USA.
Joshua J MeeksDepartment of Urology, Northwestern University Medical Center, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-5444-5510
Rian DicksteinChesapeake Urology, Hanover, MD, USA.
Shane M PearceSpokane Urology, Spokane, WA, USA.
Seok Ho KangKorea University, Anam Hospital, Seoul, South Korea.
Seung Il JungChonnam National University, Hwasun Hospital, Bundang, South Korea.
Ashish M KamatDepartment of Urology, UT MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-3546-9928
James M BurkeBillings Clinic, Billings, MT, USA.
Kirk A KeeganCG Oncology, Irvine, CA, USA.
Gary D SteinbergDepartment of Urology, Rush University Medical Center, Chicago, IL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38956199

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.